• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain.HIV-1 包膜糖蛋白介导的病毒-细胞和细胞-细胞融合被缺乏关键口袋结构域的短 gp41 N 端膜锚定肽抑制。
FASEB J. 2010 Nov;24(11):4196-202. doi: 10.1096/fj.09-151704. Epub 2010 Jul 6.
2
ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.ADS-J1通过靶向gp41 NHR三聚体中高度保守的口袋区域来抑制HIV-1感染和膜融合。
Biochim Biophys Acta. 2014 May;1838(5):1296-305. doi: 10.1016/j.bbamem.2013.12.022. Epub 2014 Jan 3.
3
Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.创建人工尾部锚定物作为增强基于肽的HIV融合抑制剂效力的新策略。
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01445-16. Print 2017 Jan 1.
4
The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.HIV-1 gp41 富含色氨酸基序可与 N 端深袋位结合:对 gp41 结构与功能及其抑制剂的新认识。
J Virol. 2019 Dec 12;94(1). doi: 10.1128/JVI.01358-19.
5
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.鉴定人类免疫缺陷病毒1型(HIV-1)gp41核心结构的关键基序:对设计新型抗HIV融合抑制剂的意义。
J Virol. 2008 Jul;82(13):6349-58. doi: 10.1128/JVI.00319-08. Epub 2008 Apr 16.
6
HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.在gp41口袋区域具有单点突变的HIV-1变体,对具有口袋或膜结合结构域的HIV融合抑制剂表现出不同的敏感性。
Biochim Biophys Acta. 2012 Dec;1818(12):2950-7. doi: 10.1016/j.bbamem.2012.07.020. Epub 2012 Jul 31.
7
Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.膜锚定的HIV-1 N-七肽重复序列肽通过改变作用模式成为高效的细胞融合抑制剂。
PLoS Pathog. 2009 Jul;5(7):e1000509. doi: 10.1371/journal.ppat.1000509. Epub 2009 Jul 10.
8
Peptide and non-peptide HIV fusion inhibitors.肽类和非肽类HIV融合抑制剂。
Curr Pharm Des. 2002;8(8):563-80. doi: 10.2174/1381612024607180.
9
Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.埋藏极性残基的疏水性突变增强了 HIV-1 gp41 N 端七肽重复 - C 端七肽重复相互作用和 C 肽的抗 HIV 活性。
AIDS. 2014 Jun 1;28(9):1251-60. doi: 10.1097/QAD.0000000000000255.
10
Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.HIV-1 gp41 衣壳蛋白 C 端七肽重复区的保守残基 Asn-145 对病毒融合至关重要,并调节融合抑制剂的抗病毒活性。
Viruses. 2019 Jul 3;11(7):609. doi: 10.3390/v11070609.

引用本文的文献

1
Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.抗逆转录病毒药物对 CCR5 CRISPR/Cas9 基因编辑——追求 HIV 治愈的范式转变。
Clin Immunol. 2023 Oct;255:109741. doi: 10.1016/j.clim.2023.109741. Epub 2023 Aug 21.
2
In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor.体外筛选和鉴定对 LP-40(一种基于恩夫韦肽的脂肽抑制剂)具有更高耐药性的 HIV-1 变异体。
Int J Mol Sci. 2022 Jun 14;23(12):6638. doi: 10.3390/ijms23126638.
3
A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.一种膜锚定的短肽融合抑制剂可完全保护靶细胞免受人类免疫缺陷病毒 1 型(HIV-1)、HIV-2 和猴免疫缺陷病毒的感染。
J Virol. 2019 Oct 29;93(22). doi: 10.1128/JVI.01177-19. Print 2019 Nov 15.
4
Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.基于蛋白质和肽的 HIV 进入抑制剂的开发,针对 gp120 或 gp41。
Viruses. 2019 Aug 1;11(8):705. doi: 10.3390/v11080705.
5
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.一种具有两个尾部锚定和棕榈酸的基于肽的 HIV-1 融合抑制剂表现出显著改善的体外和体内抗 HIV-1 活性和延长的体内半衰期。
Molecules. 2019 Mar 21;24(6):1134. doi: 10.3390/molecules24061134.
6
Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.低剂量脂肽 HIV 融合抑制剂单药治疗可维持恒河猴的长期病毒抑制。
PLoS Pathog. 2019 Feb 4;15(2):e1007552. doi: 10.1371/journal.ppat.1007552. eCollection 2019 Feb.
7
Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.基于恩夫韦肽(T20)的脂肽是一种有效的HIV-1细胞融合抑制剂:对病毒进入和抑制的意义。
J Virol. 2017 Aug 24;91(18). doi: 10.1128/JVI.00831-17. Print 2017 Sep 15.
8
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent , , and Antiviral Activity.一种具有高效、广谱抗病毒活性的脂肽HIV-1/2融合抑制剂。
J Virol. 2017 May 12;91(11). doi: 10.1128/JVI.00288-17. Print 2017 Jun 1.
9
Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.糖蛋白41胞外域的结构域交换构建体是HIV感染的有效抑制剂。
ACS Chem Biol. 2015 May 15;10(5):1247-57. doi: 10.1021/cb501021j. Epub 2015 Feb 17.
10
Early and late HIV-1 membrane fusion events are impaired by sphinganine lipidated peptides that target the fusion site.鞘氨醇酰化肽靶向融合部位,可损害 HIV-1 早期和晚期的膜融合事件。
Biochem J. 2014 Jul 15;461(2):213-22. doi: 10.1042/BJ20140189.

本文引用的文献

1
Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.膜锚定的HIV-1 N-七肽重复序列肽通过改变作用模式成为高效的细胞融合抑制剂。
PLoS Pathog. 2009 Jul;5(7):e1000509. doi: 10.1371/journal.ppat.1000509. Epub 2009 Jul 10.
2
Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.肽P5(628 - 683位氨基酸残基)包含HIV-1 gp41的整个膜近端区域及其钙结合位点,是一种有效的HIV-1感染抑制剂。
Retrovirology. 2008 Oct 16;5:93. doi: 10.1186/1742-4690-5-93.
3
Mechanics of membrane fusion.膜融合机制。
Nat Struct Mol Biol. 2008 Jul;15(7):675-83. doi: 10.1038/nsmb.1455.
4
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.病毒膜融合蛋白的结构与机制:同一主题的多种变体
Crit Rev Biochem Mol Biol. 2008 May-Jun;43(3):189-219. doi: 10.1080/10409230802058320.
5
The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide.HIV-1包膜糖蛋白gp41的膜近端外部区域有助于与匹配的N'肽形成的六螺旋束的稳定。
Biochemistry. 2008 Jul 1;47(26):6782-92. doi: 10.1021/bi7023139. Epub 2008 Jun 10.
6
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.鉴定人类免疫缺陷病毒1型(HIV-1)gp41核心结构的关键基序:对设计新型抗HIV融合抑制剂的意义。
J Virol. 2008 Jul;82(13):6349-58. doi: 10.1128/JVI.00319-08. Epub 2008 Apr 16.
7
Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains.1型人类免疫缺陷病毒Nef蛋白调节病毒粒子和宿主细胞膜微结构域的脂质组成。
Retrovirology. 2007 Oct 1;4:70. doi: 10.1186/1742-4690-4-70.
8
Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition.
FASEB J. 2007 Nov;21(13):3677-84. doi: 10.1096/fj.07-8582com. Epub 2007 Jun 15.
9
Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells.1型人类免疫缺陷病毒包膜糖蛋白三聚体在病毒进入宿主细胞过程中的亚基化学计量学
J Virol. 2006 May;80(9):4388-95. doi: 10.1128/JVI.80.9.4388-4395.2006.
10
Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.膜锚定抑制性肽捕获人类免疫缺陷病毒1型gp41在融合前与靶膜结合的构象。
J Virol. 2006 Apr;80(7):3249-58. doi: 10.1128/JVI.80.7.3249-3258.2006.

HIV-1 包膜糖蛋白介导的病毒-细胞和细胞-细胞融合被缺乏关键口袋结构域的短 gp41 N 端膜锚定肽抑制。

Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain.

机构信息

Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel.

出版信息

FASEB J. 2010 Nov;24(11):4196-202. doi: 10.1096/fj.09-151704. Epub 2010 Jul 6.

DOI:10.1096/fj.09-151704
PMID:20605950
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2974423/
Abstract

The interactions between the N- and C-terminal heptad repeat (NHR and CHR) regions of the human immunodeficiency virus (HIV-1) glycoprotein gp41 create a structure comprising a 6-helix bundle (SHB). A sequence in the SHB named the "pocket" is crucial for the SHB's stability and for the fusion inhibitory activity of 36-residue NHR peptide N36. We report that a short 27-residue peptide, N27, which lacks the pocket sequence, exhibits potent inhibitory activity in both cell-cell and virus-cell fusion assays when fatty acids were conjugated to its N but not C terminus. Furthermore, mutations in the positions that prevent interaction with the CHR but not with the NHR resulted in a dramatic reduction in N27 activity. These data support a mechanism in which N27 mainly targets the CHR rather than the internal NHR coiled-coil, reveal the N-terminal edge of the endogenous core structure in situ and hence complement our recent findings of the C-terminal edge of the core, and provide a new approach for designing short inhibitors from the NHR region of other lentiviruses due to similarities in their envelope proteins.

摘要

人类免疫缺陷病毒(HIV-1)糖蛋白 gp41 的 N-和 C-末端七肽重复(NHR 和 CHR)区域之间的相互作用形成了一个包含 6 个螺旋束(SHB)的结构。SHB 中的一个名为“口袋”的序列对于 SHB 的稳定性以及 36 个残基 NHR 肽 N36 的融合抑制活性至关重要。我们报告说,一种缺乏口袋序列的短 27 个残基肽 N27,当其 N 端而不是 C 端连接脂肪酸时,在细胞-细胞和病毒-细胞融合测定中均表现出很强的抑制活性。此外,在与 CHR 而不是 NHR 相互作用的位置发生突变会导致 N27 活性显著降低。这些数据支持了一种机制,即 N27 主要靶向 CHR 而不是内部 NHR 卷曲螺旋,原位揭示了内源性核心结构的 N 端边缘,从而补充了我们最近关于核心 C 端边缘的发现,并由于其包膜蛋白的相似性,为设计来自其他慢病毒 NHR 区域的短抑制剂提供了一种新方法。